[China Pharmaceutical: Plans to give up the right of first refusal for 24% of Chongqing Medical Health's equity] China Pharmaceutical announced that the company received a notice from Chongqing Yufu, a shareholder of its shareholding company Chongqing Medical Health, that it intends to publicly list and transfer 24% of Chongqing Medical Health's equity, with a minimum price of 2.206 billion yuan. The company decided to give up the right of first refusal for the equity. It is not yet certain whether the waiver of the right of first refusal constitutes a related transaction, and it does not constitute a major asset reorganization. The 28th meeting of the 9th Board of Directors of the company reviewed and approved the proposal, which still needs to be submitted to the shareholders' meeting for review. The waiver of the right of first refusal will not result in changes in the scope of the company's consolidated financial statements, nor will it result in a decrease in the company's shareholding in Chongqing Medical Health. There is no situation that harms the interests of the company and its shareholders, and it will not have a significant impact on the company's financial and operating conditions.
